Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation

22Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

Abstract

Haemolytic disease of the fetus and newborn (HDFN) remains an important cause of fetal mortality with potential neonatal and longer-term morbidity. HDFN is caused by maternal red cell alloimmunisation, with IgG antibodies crossing the placenta to destroy fetal erythroid cells expressing the involved antigen. Intrauterine fetal blood transfusion is the therapy of choice for severe fetal anaemia. Despite a strong evidence base and technical advances, invasive fetal therapy carries risk of miscarriage and preterm birth. Procedure-related risks are increased when invasive, in utero transfusion is instituted prior to 22 weeks to treat severe early-onset fetal anaemia. This review focuses upon this cohort of HDFN and discusses intravenous immunoglobin (IVIg) and novel monoclonal antibody (M281, nipocalimab) treatments which, if started at the end of the first trimester, may attenuate the transplacental passage and fetal effects of IgG antibodies. Such therapy has the ability to improve fetal survival in this severe presentation of HDFN when early in utero transfusion may be required and may have wider implications for the perinatal management in general.

References Powered by Scopus

FcRn: The neonatal Fc receptor comes of age

1893Citations
N/AReaders
Get full text

Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization

1036Citations
N/AReaders
Get full text

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

756Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals

65Citations
N/AReaders
Get full text

The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?

19Citations
N/AReaders
Get full text

FcRN receptor antagonists in the management of myasthenia gravis

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Castleman, J. S., Moise, K. J., & Kilby, M. D. (2021, February 1). Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. British Journal of Haematology. Blackwell Publishing Ltd. https://doi.org/10.1111/bjh.17041

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

68%

Lecturer / Post doc 4

16%

Professor / Associate Prof. 2

8%

Researcher 2

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 19

59%

Biochemistry, Genetics and Molecular Bi... 5

16%

Immunology and Microbiology 5

16%

Nursing and Health Professions 3

9%

Save time finding and organizing research with Mendeley

Sign up for free